Du är här

2016-01-21

AbCellera: AbCellera Announces Successful Completion of Collaboration for the Discovery of Fully Human Antibodies Against Pathogenic E. Coli and Ebola Virus

VANCOUVER, British Columbia, Jan. 20, 2016 (GLOBE NEWSWIRE) -- AbCellera
announced today successful completion of its first antibody discovery
partnership with MassBiologics of the University of Massachusetts Medical
School. The project, funded by the Defense Advanced Research Project Agency
(DARPA) under the ADEPT-PROTECT program, was directed towards rapid human
antibody discovery for infectious diseases.

Through this collaboration AbCellera demonstrated single cell antibody
discovery with throughput of millions of cells per experiment, allowing for
the efficient and deep screening of natural antibody responses from patients
following infection or challenge. Using AbCellera's platform, the selection
and sequencing of fully human antibodies was achieved in as little as five
days. Screening of over 10 million single B cells was used to discover a
panel of hundreds of ultra-rare antibodies against multiple targets from
enterotoxigenic Escherichia coli.
In a separate element of the collaboration, AbCellera also identified hundreds
of human anti-Ebola antibodies from a single blood sample obtained from a
convalescent human patient, and provided sequences of a select subset of
antibodies in less than a week.

Dr. Carl Hansen, CEO and co-founder of AbCellera commented: "We are very
pleased with the success of this project, which has clearly established our
platform as a powerful approach for human antibody discovery. In particular,
our data has demonstrated single cell antibody screening with combined speed,
throughput and assay flexibility that is unmatched. In addition to infectious
diseases, these capabilities are enabling for applications in
immuno-oncology, and will open new opportunities for rapid functional
profiling of human immune responses."

This work was made possible by close collaboration between team members from
AbCellera and MassBiologics within the frame of the ADEPT-PROTECT program.
"We would like to thank Dr. Mark Klempner for his leadership in this project,
as well as Drs. Colby Souders, William Thomas, Yang Wang, Keith Reimann, Lisa
Cavacini, and the larger MassBiologics scientific team. Their efforts have
made this both a very enjoyable and a productive partnership. We are grateful
for DARPA's support and it has been an honor to be of service in this
important and forward-looking initiative led by Colonel Dan Wattendorf to
bolster rapid pandemic response and biodefense." said Dr. Hansen.

For more information on AbCellera and potential partnership opportunities,
please visit www.abcellera.com or contact:

Kevin Heyries

Telephone: 604-827-4151
Email: media@abcellera.com

About AbCellera Biologics Inc.

AbCellera is a privately held biotechnology company that provides enabling
technologies for the discovery and development of monoclonal antibody (mAb)
therapies directly from natural immune cells.

AbCellera's lead technology is a proprietary single cell antibody discovery
platform that provides pharma and biotech partners with the ability to
rapidly identify mAb therapeutic candidates from the natural immune
repertoires of any species, including humans. For more information, please
visit www.abcellera.com

About MassBiologics

MassBiologics of the University of Massachusetts Medical School is the only
publicly owned, non-profit FDA-licensed manufacturer of vaccines and other
biologic products in the United States. The laboratory was established in
1894 by the state Board of Health to produce diphtheria antitoxin. Since that
time, the focus at MassBiologics has been to improve public health through
applied research, development and production of biologic products. In 1997,
the Commonwealth of Massachusetts transferred MassBiologics operations from
the Department of Public Health to UMass Medical School to "maintain their
public purpose, preserving their ability to compete in an increasingly
competitive marketplace and to maximize their value to the Commonwealth."

About the University of Massachusetts Medical School

The University of Massachusetts Medical School has built a reputation as a
world-class research institution, consistently producing noteworthy advances
in clinical and basic research. The Medical School attracts more than $270
million in research funding annually, 80 percent of which comes from federal
funding sources. The mission of the Medical School is to advance the health
and well-being of the people of the commonwealth and the world through
pioneering education, research, public service and health care delivery with
its clinical partner, UMass Memorial Health Care. For more information, visit
http://www.umassmed.edu/.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AbCellera via Globenewswire

HUG#1980317

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.